Last checked at 
ReNeuron Group PLC - the cell-based therapeutics developer - signed a new research evaluation agreement with an undisclosed US biotechnology company in connection with the use of its exosomes for the delivery of novel gene silencing therapeutics. This latest research collaboration will focus on the use of ReNeuron's human neural stem cell-derived exosomes for the delivery of the US biotechnology company's neuroscience therapeutic candidates. ReNeuron will be responsible for manufacturing exosomes and then loading them with the gene silencing sequences after which the US biotechnology company will evaluate the loaded exosomes. Assuming positive results, the parties will jointly own the novel therapeutic candidate created for future development.
Current stock price: 136.50 pence
Year-to-date change: down 5.2%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
